BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices.
Business Model:
Revenue: $10.7M
Employees: 2-10
Address: Seestrasse 16
City:
State: zurich
Zip: 8700
Country: CH
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2009 | Orthocon | Series B | 25M |
6/2014 | Natural Dental Implants | Series A | 1.4M |
2/2008 | BioVascular | Series C | 10.9M |
1/2014 | Sonetik | Series A | - |
4/2009 | Aerovance | Venture Round | 38M |
4/2013 | Radius Health | Private Equity Round | 43M |
8/2007 | Alpex Pharma | Series B | 9M |
11/2003 | Auxilium Pharmaceuticals | Series D | 43M |
12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
8/2007 | Pevion Biotech | Series A | 29.2M |
2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
12/2016 | Abyrx | Venture Round | 0 |
9/2011 | AM Pharma | Series D | 39.9M |
9/2014 | AM Pharma | Series E | 15.8M |
9/2005 | TargeGen | Series C | 30M |
2/2006 | Orthocon | Series A | 10M |
1/2006 | Tioga Pharmaceuticals | Series A | 24M |
12/2005 | Optimer Pharmaceuticals | Series D | 22.2M |
1/2017 | Binx Health | Series D | 0 |
8/2009 | Palyon Medical | Series A | 24M |
10/2013 | Opsona | Series C | 0 |
4/2013 | Opsona | Series C | 0 |
1/2015 | Binx Health | Series C | 0 |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
4/2007 | Radius Health | Series B | 57.5M |
3/2006 | BioXell | Series C | 12.7M |
7/2011 | Binx Health | Series B | 27.1M |
8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
9/2022 | Rivus Pharmaceuticals | Series B | 132M |
7/2011 | Radius Health | Series C | 66M |
12/2011 | Radius Health | Private Equity Round | 21.4M |
11/2008 | Radius Health | Series C | 15M |
4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
10/2004 | BioXell | Series C | 29M |
3/2020 | AM Pharma | Venture Round | 25.4M |
8/2007 | Molecular Partners | Series A | 15.6M |
12/2009 | Molecular Partners | Series B | 44.2M |
5/2016 | Aleva Neurotherapeutics | Series C | 18M |
2/2018 | Moderna Therapeutics | Series G | 0 |
1/2011 | VAXIMM | Venture Round | 8M |
4/2014 | Binx Health | Series B | 0 |
9/2008 | Lumavita | Series A | 16.2M |
7/2007 | TargeGen | Series D | 40M |
8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
3/2020 | AM Pharma | Venture Round | 0 |
12/2019 | Aleva Neurotherapeutics | Series E | 0 |
2/2018 | Moderna Therapeutics | Series G | 0 |
1/2017 | Binx Health | Series D | 0 |
12/2016 | Abyrx | Venture Round | 0 |
5/2016 | Aleva Neurotherapeutics | Series C | 0 |
1/2015 | Binx Health | Series C | 0 |
9/2014 | AM Pharma | Series E | 0 |
6/2014 | Natural Dental Implants | Series A | 0 |
4/2014 | Binx Health | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|